Showing results (101-110 of 166) with videos related to
Sort By:
Pageof 17
European Journal of Heart Failure|July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.Journal of the American Heart Association|April 14, 2018
Outcomes in Asymptomatic Severe Aortic Stenosis With Preserved Ejection Fraction Undergoing Rest and Treadmill Stress EchocardiographyChetan P Huded, Ahmad Masri, Kenya Kusunose, et al.European Journal of Heart Failure|July 31, 2020
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosisHannah Rosenblum, Ahmad Masri, David L Narotsky, et al.Journal of the American Heart Association|November 26, 2025
Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort StudyBrett W Sperry, Ahmad Masri, Prem Soman, et al.Journal of the American Heart Association|March 7, 2025
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyBryton J Davis, Hailey Volk, Olives Nguyen, et al.JAMA Cardiology|January 18, 2023
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized TrialMatthew T Wheeler, Iacopo Olivotto, Perry M Elliott, et al.JACC. Cardiooncology|April 17, 2025
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid CardiomyopathyAhmad Masri, Priyanka Bhattacharya, Brent Medoff, et al.European Journal of Heart Failure|May 30, 2026
Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CMMarianna Fontana, Francesco Cappelli, Pablo Garcia-Pavia, et al.Journal of the Peripheral Nervous System : JPNS|November 8, 2022
Liver-directed drugs for transthyretin-mediated amyloidosisThomas H Brannagan, John L Berk, Julian D Gillmore, et al.European Journal of Heart Failure|March 2, 2026
Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: Observations from ATTRibute-CMFrancesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, et al.Pageof 17